TY - JOUR
T1 - Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer
AU - Shiota, Masaki
AU - Yokomizo, Akira
AU - Takeuchi, Ario
AU - Kiyoshima, Keijiro
AU - Inokuchi, Junichi
AU - Tatsugami, Katsunori
AU - Naito, Seiji
N1 - Funding Information:
Grant support This work was supported by the Kakenhi grants (24890160 and 25462484) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT), Japan, and a Research Promotion Grant from the Kanae Foundation for the Promotion of Medical Science (to MS), Japan.
Publisher Copyright:
© 2014, Springer-Verlag Berlin Heidelberg.
PY - 2014/12
Y1 - 2014/12
N2 - Purpose: Docetaxel is a standard therapy for patients with castration-resistant prostate cancer (CRPC). However, docetaxel-associated adverse events (AEs) such as febrile neutropenia (FN) can impair quality of life and may become life-threatening. In this study, we clarified the AEs and risk factors associated with FN in clinical settings.Methods: This study included 37 Japanese patients with CRPC who were treated with 70–75 mg/m2 docetaxel and 10 mg prednisone every 3 or 4 weeks between 2008 and 2012. AEs, risk factors for FN, and the prognostic significance of several clinicopathological factors were analyzed.Results: Hematological AEs of ≥grade 3 included neutrocytopenia in 36 patients (97.3 %), leukopenia in 24 patients (64.9 %), lymphopenia in 10 patients (27.0 %), and FN in 4 patients (10.8 %). In addition, severe non-hematological AEs included colonic perforation, interstitial pneumonia, and acute respiratory distress syndrome in 1 patient each. Severe lymphopenia was positively associated with the incidence of FN. Low serum albumin and low lymphocyte count were identified as possible pre-treatment risk factors, while severe lymphopenia was identified as a post-treatment risk factor.Conclusions: Non-hematological AEs as well as substantial hematological AEs were recognized in the Japanese population treated with docetaxel chemotherapy against CRPC. Pre- and post-treatment lymphopenia and pre-treatment serum albumin should be considered in order to minimize the risk of FN when selecting patients with prostate cancer for docetaxel therapy, and when considering dose modifications, and the prophylactic use of granulocyte colony-stimulating factor.
AB - Purpose: Docetaxel is a standard therapy for patients with castration-resistant prostate cancer (CRPC). However, docetaxel-associated adverse events (AEs) such as febrile neutropenia (FN) can impair quality of life and may become life-threatening. In this study, we clarified the AEs and risk factors associated with FN in clinical settings.Methods: This study included 37 Japanese patients with CRPC who were treated with 70–75 mg/m2 docetaxel and 10 mg prednisone every 3 or 4 weeks between 2008 and 2012. AEs, risk factors for FN, and the prognostic significance of several clinicopathological factors were analyzed.Results: Hematological AEs of ≥grade 3 included neutrocytopenia in 36 patients (97.3 %), leukopenia in 24 patients (64.9 %), lymphopenia in 10 patients (27.0 %), and FN in 4 patients (10.8 %). In addition, severe non-hematological AEs included colonic perforation, interstitial pneumonia, and acute respiratory distress syndrome in 1 patient each. Severe lymphopenia was positively associated with the incidence of FN. Low serum albumin and low lymphocyte count were identified as possible pre-treatment risk factors, while severe lymphopenia was identified as a post-treatment risk factor.Conclusions: Non-hematological AEs as well as substantial hematological AEs were recognized in the Japanese population treated with docetaxel chemotherapy against CRPC. Pre- and post-treatment lymphopenia and pre-treatment serum albumin should be considered in order to minimize the risk of FN when selecting patients with prostate cancer for docetaxel therapy, and when considering dose modifications, and the prophylactic use of granulocyte colony-stimulating factor.
UR - http://www.scopus.com/inward/record.url?scp=84929941131&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929941131&partnerID=8YFLogxK
U2 - 10.1007/s00520-014-2328-7
DO - 10.1007/s00520-014-2328-7
M3 - Article
C2 - 24996830
AN - SCOPUS:84929941131
VL - 22
SP - 3219
EP - 3226
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
SN - 0941-4355
IS - 12
ER -
